This study demonstrated for the first time that the FIGNL1-HMMR-ECM receptor signaling axis regulates the formation of HCC, which provides a basis for future research and development of molecular-targeted drugs targeting this signaling axis. The gene discussed is FIGNL1; the disease is hepatocellular carcinoma.